检测与治疗:实施耐多药结核病新方案的意义
世界卫生组织近期推荐了一种治疗耐多药结核病的更短程新方案,但如何最恰当地使用药物敏感性检测(DST)来支持该方案尚不明确。实施国家常需在采用标准化方案(尽管存在高水平潜在耐药)与要求更严格的DST之间选择,前者可能使患者暴露于氟喹诺酮类药物的实际单药治疗,后者可能将大量患者排除在最有效治疗之外。作者讨论这一困境,主张将DST整合到任何新型抗菌方案的实施中,但避免过度严格的要求。
要点
- 世界卫生组织推荐了更短程的耐多药结核病新方案。
- 实施国家面临标准化方案与严格DST要求之间的选择困境。
- 作者主张将DST整合到新方案实施中,避免过度严格。
核心结论
- 作者主张将药物敏感性检测整合到任何新型抗菌方案的实施中,但不应设置过度严格的要求。
研究设计与样本
- 原文为述评,未报告系统检索范围或样本量。
主要发现
- 采用标准化方案尽管存在高水平潜在耐药,可能使患者暴露于氟喹诺酮类药物的实际单药治疗。
- 要求更严格的DST可能将大量患者排除在最有效治疗选项之外。
临床怎么用
- 作者认为,将DST整合到新方案实施中且不过度严格,可使新型耐多药结核病方案惠及多数患者,同时降低产生额外耐药的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A novel, shorter-course regimen for treating multidrug-resistant (MDR) tuberculosis was recently recommended by the World Health Organization. However, the most appropriate use of drug susceptibility testing (DST) to support this regimen is less clear. Implementing countries must therefore often choose between using a standardized regimen despite high levels of underlying drug resistance or require more stringent DST prior to treatment initiation. The former carries a high likelihood of exposing patients to de facto monotherapy with a critical drug class (fluoroquinolones), whereas the latter could exclude large groups of patients from their most effective treatment option. We discuss the implications of this dilemma and argue for an approach that will integrate DST into the delivery of any novel antimicrobial regimen, without excessively stringent requirements. Such guidance could make the novel MDR tuberculosis regimen available to most patients while reducing the risk of generating additional drug resistance.
引用
- Dowdy DW, Theron G, Tornheim JA, et al. Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2017. PMID: 29554229. doi:10.1093/cid/cix486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。